Prevnar 13®

BIOLOGICAL11 trials

Sponsors

Merck Sharp & Dohme LLC, GlaxoSmithKline, MCM Vaccines B.V., Sanofi Pasteur, a Sanofi Company

Conditions

Bacterial InfectionsHaemophilus Influenzae Type bInfections, StreptococcalMeningococcalNeisseria MeningitidisPneumococcal ImmunizationPneumococcal InfectionsStreptococcus Pneumoniae Infection

Phase 1

Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

CompletedNCT02037984

Merck Sharp & Dohme LLCPneumococcal Infections, Streptococcus Pneumoniae Infection

Start: 2014-01-28End: 2016-07-01Updated: 2019-06-24

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

CompletedNCT06698198

Sanofi Pasteur, a Sanofi CompanyPneumococcal Immunization

Start: 2018-12-03End: 2019-09-30Updated: 2024-11-20

Phase 2

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

CompletedNCT01215188

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2010-10-14End: 2012-07-31Updated: 2019-04-30

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

CompletedNCT01513551

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2012-03-13End: 2013-02-15Updated: 2018-12-13

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

CompletedNCT01545375

GlaxoSmithKlineInfections, Streptococcal

Start: 2012-05-21End: 2016-07-26Updated: 2019-12-27

Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

CompletedNCT02547649

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2015-10-08End: 2016-01-20Updated: 2019-04-16

Phase 3

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

CompletedNCT01553279

MCM Vaccines B.V.Bacterial Infections, Neisseria Meningitidis, Virus Diseases

Start: 2012-03-30End: 2013-09-27Updated: 2019-03-28

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

CompletedNCT01978093

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2014-02-01End: 2016-03-18Updated: 2018-09-14

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

CompletedNCT03885934

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-06-25End: 2020-12-09Updated: 2023-01-13

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

CompletedNCT03950622

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-06-13End: 2020-03-30Updated: 2021-04-26

Phase 4

A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays

CompletedNCT02072525

GlaxoSmithKlineMeningococcal

Start: 2014-04-01End: 2015-06-02Updated: 2017-11-27

Related Papers

A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN).

2022-09-2113 citations

Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE)

Japanese Journal of Infectious Diseases2022-07-285 citations

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)

Vaccine2021-09-0887 citations

Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study

Vaccine2019-10-1640 citations

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

2019-02-1545 citations

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.

2019-01-1672 citations

Immunogenicity and safety of the <i>Haemophilus influenzae</i> type b and <i>Neisseria meningitidis</i> serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants

Human Vaccines & Immunotherapeutics2018-09-254 citations

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.

2018-09-2176 citations

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.

2018-03-1732 citations